Journal of Obesity & Metabolic Syndrome



Korean J Obes 2011; 20(1): 16-22

Published online March 1, 2011

Copyright © Korean Society for the Study of Obesity.

The Association of Homocysteine and Metabolic Syndrome

Kyoung Pil Shin(1), Sang-Yeoup Lee(2).(3), Yun Jin Kim(1).(4), Jeong Gyu Lee(1).(4)*, Dong-Hee Kim(5), Dong-Wook Jung(2), Yu-Hyeon Yi(4), Seon Ki Park(2), Young-Hye Cho(2)

Department of Family Medicine, Pusan National University School of Medicine(1), Family Medicine Clinic, Pusan National University Yangsan Hospital(2), Medical Education Unit, Pusan National University School of Medicine(3), Department of Family Medicine, Pusan National University Hospital(4), College of Nursing, Pusan National University(5)

Background: Metabolic syndrome is a cluster of all the risk factors of cardiovascular diseases, in which insulin resistance plays a key role as the pathogenesis.
Homocysteine is an amino acid that is generated during methionine metabolism. It is associated with insulin resistance. However, there is a controversy concerning the corelation between homocysteine and metabolic syndrome.
This study is designed to further investigate this subject.
Methods: A total of 4488 patients who were older than 20 years of age and visited the Health Promotion Center of a university affiliated hospital from Jan 1, 2007 to Dec 31, 2007 were assigned to this study. Modified ATP III definition was used for diagnosis of metabolic syndrome while Korean standard for waist circumference was used.
This study tried to prove the correlation of homocysteine concentration and metabolic syndrome by using two statistical tools. The first was the comparison of homocysteine concentration between the group with and without metabolic syndrome. The second was the prevalence ratio of metabolic syndrome according to the level of homocysteine concentration.
Results: The group with metabolic syndrome showed a significantly higher level of homocysteine compared to the other groups (9.10 vs 7.97, P < 0.001). In comparison to the group with the lowest (< 5.90 mg/L, Q1) homocysteine level, the prevalence of metabolic syndrome among the other groups (Q2.Q3 and Q4) were significantly higher with odds ratio being 1.28, 1.48 and 1.41 for groups Q2, Q3, and Q4, respectively.
Conclusion: Metabolic syndrome was shown to have a significant correlation with a high level of homocysteine.
Therefore, lowering homocysteine level may help prevent metabolic syndrome.

Keywords: Homocysteine, Metabolic syndrome, Prevention of metabolic syndrome, Insulin resistance

Demographic and clinical characteristics of study group

Correlation of serum homocysteine level and markers of cardiovascular risk

Prevalence of metabolic syndrome according to quartiles of serum homocysteine (mean ± SD)

Logistic regression analysis for metabolic syndrome

  1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lathi K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
    Pubmed CrossRef
  2. Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992;24:465-8.
    Pubmed CrossRef
  3. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14.
    Pubmed CrossRef
  4. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel Ⅲ). JAMA 2001;285:2486-97.
  5. Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L, et al. Effects of a high fat sucrose diet in enzymes in homocysteine metabolism in the rat. Metabolism 2000;49:736-41.
    Pubmed CrossRef
  6. Loverro G, Korusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002;53:157-62.
    Pubmed CrossRef
  7. George N Welch, Joseph L Oscalzo, PH D. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
    Pubmed CrossRef
  8. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
    Pubmed CrossRef
  9. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
    Pubmed CrossRef
  10. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997;277:1775-81.
    Pubmed CrossRef
  11. den Heijer M, Kostor T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
    Pubmed CrossRef
  12. Lentz SR. Homocysteine and vascular dysfunction. Life Sci 1997;61:1205-15.
  13. Cattaneo M. Hyperhomocysteinemia and thrombosis. Lipids 2001;36 suppl:S13-26.
  14. Wilcken DE, Gupta VJ. Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979;9:301-7.
  15. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int suppl 1993;41:S72-7.
  16. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinants for diagnosing cobalamin and folate deficiencies. Am J Med 1994;96:239-46.
  17. McCully KS. Homocysteine and vascular disease. Nat Med 1996;2:386-9.
    Pubmed CrossRef
  18. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
  19. WHO. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation. Geneva, Switzerland: World Health Organization; 2000.
  20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Teacher DF, Turner RC. Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
    Pubmed CrossRef
  21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, Blood Institute scientific statement. Circulation 2005;112:2735-52.
    Pubmed CrossRef
  22. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract 2007;75:72-80.
    Pubmed CrossRef
  23. Important cause of death in Korea; 2005. Seoul:Korea National Statistical Office 2005.
  24. Park JS, Park HD, Yun JW, Jung CH, Lee WY, Kim SW. Prevalence of the metabolic syndrome as defined by NCEP-ATPⅢ among the urban Korean population. The Korean Journal of Medicine 2002;63:290-8.
  25. Park SH, Lee WY, Kim SW. The relative risks of the metabolic syndrome defined by adult treatment panel 3 according to insulin resistance in Korean population. The Korean Journal of Medicine 2003;64:552-60.
  26. Bjorck J, Hellgren M, Rastam L, Lindblad U. Associations between serum insulin and homocysteine in a Swedish population-a potential link between the metabolic syndrome and hyperhomocysteinemia: the Skaraborg project. Metabolism 2006;55:1007-13.
    Pubmed CrossRef
  27. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997;46 Suppl 2:S9-13.
  28. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 2001;24:1403-10.
    Pubmed CrossRef